Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination with Pfizer’s ADCs

CAR-T Digest - August 2020

Weekly Digest - February 2025

24 Feb 2025: Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination with Pfizer’s ADCs

Akeso announced that its partner, Summit Therapeutics, has collaborated with Pfizer to evaluate ivonescimab, a PD-1/VEGF bispecific antibody. The trials will test ivonescimab in combination with Pfizer’s ADCs across multiple solid tumor types
The collaboration aims to accelerate the development of innovative treatment combinations that could improve standards of care for patients with serious unmet medical needs
The clinical trials will assess the safety and anti-tumor activity of ivonescimab with Pfizer’s vedotin-based ADCs in different solid tumor settings
Summit will provide ivonescimab, while Pfizer will conduct the clinical trials, with both companies overseeing the studies and retaining their respective product rights
The studies are expected to begin in mid-2024, with further details on the trials to be announced later by Summit
Pfizer sees the collaboration as an opportunity to explore innovative, rational drug combinations that address the complexities of tumor biology and potentially transform cancer treatment